CytoSorbents Nabs Breakthrough Designation for Blood Purification Technology

The FDA issued a breakthrough designation for CytoSorbents’ CytoSorb blood purification technology for treating inflammation and cytokine storm.

The agency granted the designation for the removal of the blood thinner ticagrelor during cardiothoracic surgery.

The device is CE marked for reducing cytokines and other inflammatory mediators in patients with hyperinflammatory and infectious conditions.